These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27077121)

  • 1. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks.
    Wollacott AM; Boni MF; Szretter KJ; Sloan SE; Yousofshahi M; Viswanathan K; Bedard S; Hay CA; Smith PF; Shriver Z; Trevejo JM
    EBioMedicine; 2016 Mar; 5():147-55. PubMed ID: 27077121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
    Hershberger E; Sloan S; Narayan K; Hay CA; Smith P; Engler F; Jeeninga R; Smits S; Trevejo J; Shriver Z; Oldach D
    EBioMedicine; 2019 Feb; 40():574-582. PubMed ID: 30638863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study.
    Sloan SE; Szretter KJ; Sundaresh B; Narayan KM; Smith PF; Skurnik D; Bedard S; Trevejo JM; Oldach D; Shriver Z
    Antiviral Res; 2020 Dec; 184():104763. PubMed ID: 32151645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
    Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.
    Leyva-Grado VH; Tan GS; Leon PE; Yondola M; Palese P
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4162-72. PubMed ID: 25941218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.
    Mallory RM; Ali SO; Takas T; Kankam M; Dubovsky F; Tseng L
    Biologicals; 2017 Nov; 50():81-86. PubMed ID: 28844541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
    Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
    JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
    McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C; Man CY; Henderson FW; McElhaney JE; Hampel FC; Bettis R; Kudule L; Harris J; Yates P; Tisdale M; Webster A
    Clin Ther; 2007 Aug; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A broadly neutralizing human monoclonal antibody is effective against H7N9.
    Tharakaraman K; Subramanian V; Viswanathan K; Sloan S; Yen HL; Barnard DL; Leung YH; Szretter KJ; Koch TJ; Delaney JC; Babcock GJ; Wogan GN; Sasisekharan R; Shriver Z
    Proc Natl Acad Sci U S A; 2015 Sep; 112(35):10890-5. PubMed ID: 26283346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
    Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study.
    Li S; Wu X; Li N; Cao G; Wang J; Chen Y; Li S; He J; Wu J; Yang H; Lin K; Qiu C; Liu A; Zhou H; Adrian F; Schweizer L; Zhang W; Gu J; Zhang J
    Front Pharmacol; 2023; 14():1117293. PubMed ID: 37332355
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.
    Deng R; Lee AP; Maia M; Lim JJ; Burgess T; Horn P; Derby MA; Newton E; Tavel JA; Hanley WD
    Clin Pharmacokinet; 2018 Mar; 57(3):367-377. PubMed ID: 28639229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Lim JJ; Derby MA; Zhang Y; Deng R; Larouche R; Anderson M; Maia M; Carrier S; Pelletier I; Girard J; Kulkarni P; Newton E; Tavel JA
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.
    Gow JM; Tsuji WH; Williams GJ; Mytych D; Sciberras D; Searle SL; Mant T; Gibbs JP
    Arthritis Res Ther; 2015 Oct; 17():282. PubMed ID: 26449617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
    Ledgerwood JE; Coates EE; Yamshchikov G; Saunders JG; Holman L; Enama ME; DeZure A; Lynch RM; Gordon I; Plummer S; Hendel CS; Pegu A; Conan-Cibotti M; Sitar S; Bailer RT; Narpala S; McDermott A; Louder M; O'Dell S; Mohan S; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Mascola JR; Graham BS;
    Clin Exp Immunol; 2015 Dec; 182(3):289-301. PubMed ID: 26332605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.